How your CV stacks up
Upload your CV to see how well it fits this job role
?%
Imaging Scientist or Sn Imaging Scientist (depending on expertise)
Company: Image Analysis Group (IAG)
Reports to: CEO / Head of Medical and Scientific Affairs
Location: Flexible, preferred: London (hybrid) or Boston (USA) or Hyderbad (India)
Level: Senior
About the role
IAG is the imaging CRO that pharma and biotech partners rely on when their trial hinges on getting the imaging endpoint right — MRI, CT, PET, X‑ray, ultrasound.
Sponsors come to us with a molecule, a mechanism, a target population, and a draft protocol, and expect us to translate that into a defensible, regulator-ready imaging endpoint strategy — often in days, not weeks.
We are hiring a Imaging Scientist to own that translation end‑to‑end across one or several therapeutic areas that IAG supports: musculoskeletal, rheumatology, myositis and neuromuscular, oncology (solid tumor and hematologic), obesity and metabolic disease, cardiovascular, hepatology (NASH / MASH), CNS and neurodegeneration, ophthalmology, rare disease, and emerging modalities.
You will be the person who reads a sponsor protocol and, develops imaging read plan, identifies Radiology experts and work with them to establish reader workflow. You will be speaking to the Sponsors about the endpoints, sampling approach that fits their scientific question, what the regulator will accept, what the literature supports, and where their design will fail.
What you will actually do
- Read sponsor protocols and extract every imaging endpoint, acquisition specification, sampling scheme (single-slice, limited stack, whole-organ volumetric), reader paradigm, and analysis plan. Identify gaps, contradictions, and regulatory risks in the first pass.
- Recommend the imaging endpoint architecture for the trial: primary vs secondary vs exploratory, biomarker qualification path, regulatory precedent, sensitivity to expected treatment effect, powered sample size implications.
- Defend every design choice with primary literature. For any endpoint, be able to produce the validation studies, correlation coefficients, cohort characteristics, longitudinal responsiveness data, and consensus statements that justify the choice.
- Compare sampling strategies quantitatively. Single axial slice at a fixed anatomical landmark vs limited-stack (5–7 slices) vs whole-organ volumetric — know when each is acceptable, when each will fail, and which is the right fit for the sponsor's therapeutic hypothesis, endpoint sensitivity, budget, and timeline.
- Own the consensus and regulatory landscape for therapeutic areas where you have expertise, eg ENMC (myositis), OMERACT (RA, PsA, axial SpA), RECIST / iRECIST / mRECIST / iwCLL / Lugano / RANO (oncology), LI‑RADS, PI‑RADS, BI‑RADS (organ-specific radiology), FNIH consortium biomarkers, EMA and FDA imaging biomarker qualification frameworks, ACR‑ECR imaging guidance.
- Author the imaging sections of sponsor protocols, imaging charters, statistical analysis plans, and regulatory submissions. Draft language that is precise enough to survive an FDA or EMA review and pragmatic enough to run in multi-site studies.
- Build sponsor-facing decks — endpoint frameworks, sampling defensibility matrices, mechanism-of-action to imaging biomarker maps, decision guides, investigator training — publication-quality visuals, citation-grounded, ready to send.
- Advise on cross-therapeutic technique transfer. For instance, when Dixon MFF is validated in obesity, know how (and whether) it translates to myositis, muscular dystrophy, sarcopenia, and NASH thigh sub-studies. When DCE‑MRI is standard in oncology, know its role in inflammatory arthritis and IBD. Move techniques across indications with scientific rigor.
- Turn around scientific questions. Sponsors and internal team will be coming to you with questions about the protocol and delivery.
- Represent IAG externally at ASCO, EULAR, ACR, ECR, RSNA, Bio, AAOS, OARSI, and modality-specific meetings (ISMRM, SNMMI). Publish selectively on IAG methodology.
Reasons to use Rodeo
Start with a chat, not a search bar
Grad scheme, placement, apprenticeship? Not sure what you want yet — that's fine. Your agent talks it through with you and turns "I have no idea" into a shortlist.
It searches the market for you
Every day your agent scans the market matching roles against what actually matters to you, not just keywords on a CV.
Only hits
No noise. No "maybe this fits." Just roles with a clear explanation of why they're right — and where to focus when applying.
What we need you to already know in at least 1 therapeutic area:
Modalities:
- MRI (structural, Dixon, T1/T2 mapping, DCE, DWI, MR spectroscopy, MR elastography, whole-body)
- CT (structural, quantitative, dual-energy)
- PET (FDG, amyloid, tau, PSMA, FAPI, tracer development pipeline)
- X‑ray (radiography, DXA)
- Ultrasound (musculoskeletal, elastography, contrast-enhanced)
- Optical coherence tomography, fundus, digital pathology as a companion.
Endpoints:
Rheumatology / MSK: RAMRIS, PsAMRIS, SPARCC, HOAMS, MOAKS, WORMS, Sharp/van der Heijde, cartilage T2/T1ρ, synovitis scoring, bone marrow edema
Myositis / neuromuscular: ENMC 2023 IIM consensus, Mercuri and Fischer scales, MFF (Dixon), muscle volume, T2 mapping, DTI, edema vs fatty replacement paradigm
Oncology: RECIST 1.1, iRECIST, mRECIST, Lugano, iwCLL, RANO / RANO‑BM / iRANO, Cheson, Deauville, PERCIST, tumor volumetrics, ADC as biomarker, radiomics
Obesity / metabolic: Dixon MFF, VAT/SAT/IMAT quantification, MR spectroscopy for IHTG, MRI-PDFF, single-slice vs multi-slice vs whole-body sampling
Hepatology: MRI‑PDFF, MRE, LI‑RADS, cT1, FibroScan concordance
CNS: volumetric MRI (hippocampal, whole-brain, ventricular), amyloid and tau PET SUVR, DTI, resting-state fMRI, ARIA monitoring
Cardiovascular: cardiac MRI (LGE, T1/T2 mapping, ECV), CT coronary, strain imaging
Ophthalmology: OCT, OCT‑angiography, fundus AI
Analysis and reader paradigms:
- semi-quantitative scoring
- quantitative segmentation (manual, semi-automated, deep-learning)
- single-reader vs double-read with adjudication
- blinded independent central review
- reader training and drift management
- ICC and Bland–Altman validation
- longitudinal responsiveness (SRM, effect size, MDC)
Good to have - Regulatory:
- FDA biomarker qualification pathway
- EMA qualification advice
- C‑Path consortia
- IMI / IHI biomarker programs
- imaging charter conventions
- 21 CFR Part 11
- Type C meeting preparation
Get help with your application
Your very own career expert that helps elevate your application to the next level.
Qualifications
Required:
- PhD or MD/PhD in medical physics, biomedical engineering, radiology, nuclear medicine, biomedical imaging, or a directly relevant field. MSc with 7+ years of directly equivalent industry experience considered.
- 3+ years working with imaging endpoints in clinical trials — CRO, sponsor imaging team, academic imaging core lab, or biomarker consultancy.
- Demonstrable track record of authoring imaging charters, protocol imaging sections, or SAP imaging appendices for interventional trials.
- Fluent in the primary literature — able to name the seminal validation study for any commonly used imaging endpoint in your covered therapeutic areas and quote the correlation coefficient from memory.
- Direct experience with at least three of: rheumatology, myositis / neuromuscular, oncology, metabolic / obesity, hepatology, CNS.
- Comfort speaking to sponsors at CMO / CSO / VP Clinical level — you will be the imaging expert in the room.
Preferred:
- Prior experience at an imaging CRO, imaging core lab, or the imaging team at a large sponsor (Novartis, Roche, Lilly, Novo Nordisk, Pfizer, BMS, Regeneron, Sanofi, etc.).
- Track record of successful FDA / EMA interactions on imaging biomarker questions.
- Publications on imaging biomarker validation, sampling strategies, or endpoint sensitivity.
- Familiarity with DYNAMIKA or comparable trial-imaging platforms.
Traits that matter more than the résumé
- Fast, disciplined literature reflex. When a sponsor asks a question, you can produce defensible primary references.
- Comfort saying "the design will not work" to a sponsor and immediately proposing the fix with the evidence to support it.
- Cross-indication transfer instinct. You see that a Dixon MFF technique validated in obesity has a clean read-across to myositis, sarcopenia, and NASH thigh sub-studies, and you use that connection.
- Precision in writing. Sponsor charters and regulatory submissions are read line by line. Every sentence must survive a reviewer.
- Bias to visual synthesis. Complex endpoint frameworks live better as a well-designed one-page matrix than in prose.
- Owner mentality. Nobody hands you the answer — you go find it, verify it, and cite it.
What you will get
- Direct partnership with the C-level and KOLs on every strategic sponsor engagement
- Exposure to the full spectrum of therapeutic areas, modalities, and molecule classes moving through global pharma pipelines
- Authority to shape IAG's scientific position and thought leadership across imaging in trials
- The platform (DYNAMIKA, IAG's imaging infrastructure, publication track, conference presence) to build a category-defining scientific reputation
- Competitive base + performance bonus + equity discussion at Principal / Director level
To apply:
Send CV and a short cover note describing the most technically challenging imaging endpoint problem you have solved for a sponsor, and what you would have done
“It took my CV and asked me questions relevant to understanding what kind of jobs to suggest for me. Suggestions were almost perfect. Jobs were exactly what I’ve been looking for.”
Jessica, London
Skills
Location